Please login to the form below
Xiidra
This page shows the latest Xiidra news and features for those working in and with pharma, biotech and healthcare.
Novartis to sell eye-care products to Bausch + Lomb in deal worth up to $2.5bn
Bausch said the acquisition of Xiidra would complement its existing dry eye portfolio that currently features Miebo (perfluorohexyloctane ophthalmic solution), which was recently approved in the US for DED. ... Novartis said it would continue to supply
Latest news
-
Takeda sells blockbuster-in-waiting Xiirda to Novartis for $5.3bn
Xiidra was first launched in the US in 2016, and generated sales of around $400m last year. ... Xiidra, with its unique dual benefits, is an example of the type of innovative advances we invest in for the benefit of patients," said Paul Hudson, CEO
-
Shire files dry eye drug lifitegrast in Europe
Analysts predict Xiidra could become a $1bn product. Shire is awaiting the go-ahead of lifitegrast in the EU, seeking approval for the would-be dry eye disease blockbuster. ... The Anglo-Irish company claimed approval for first-in-class LFA-1 antagonist
-
Shire licences Parion dry eye drug in $535m deal
All told the deal could be worth up to $535m for North Carolina biotech Parion, while Shire adds to the pipeline behind its recently-approved dry eye disease therapy Xiidra (lifitegrast). ... That is a different mechanism of action to current drugs
-
Shire launches dry eye drug Xiidra in US
Shire's recently-approved dry eye disease drug Xiidra is now available in the US, throwing down a challenge to Allergan's rival therapy Restasis. ... That gives Xiidra a broader label than Restasis (cyclosporine) that analysts suggest could catapult it
-
FDA finally approves Shire’s potential blockbuster Xiidra
Xiidra is tipped to be a $1bn product and is one of the stars of the Ireland-based manufacturer's pipeline. ... The only prescription eye drop indicated for the treatment of both signs and symptoms of this condition, Xiidra (lifitegrast ophthalmic
More from news
Approximately 3 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
According to Bloomberg, the products Xiidra eyedrops for dry eye and Natpara for hypoparathyroidism may be considered as a source of funds to reduce the debt Takeda will incur in the
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
Red Thread
Blending brilliant writing with in-depth market access and reimbursement expertise...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
